EGFR and lung carcinoma: A recent study from the perspective of the Chinese healthcare system investigated the cost-effectiveness of first-line erlotinib compared with platinum-doublet chemotherapy in advanced EGFR mutation positive lung cancer patients based on outcomes from the OPTIMAL trial (42).